Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PON1 | P27169 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6063365 | 0.88 | ALDH1A1 (0.39) | PON1KMT2AMAPK1KDM4ERAB9A | |
| SCHEMBL442987 | 0.87 | ALDH1A1 (0.42) | PON1KMT2AMAPK1KDM4ERAB9A | |
| SCHEMBL5872304 | 0.81 | PON1 (0.32) | PON1KMT2AMAPK1KDM4ERAB9A | |
| SCHEMBL15890143 | 0.81 | TSHR (0.36) | PON1KMT2AMAPK1KDM4ERAB9A | |
| SCHEMBL31413661 | 0.81 | PON1 (0.35) | PON1KMT2AMAPK1KDM4ERAB9A | |
| SCHEMBL3403920 | 0.78 | KMT2A (0.33) | KMT2AALDH1A1NPSR1TSHR | |
| SCHEMBL1336683 | 0.78 | PGK1 (0.42) | PON1KMT2AMAPK1KDM4ERAB9A | |
| SCHEMBL11720817 | 0.77 | KDM4E (0.30) | PON1KMT2AMAPK1KDM4ERAB9A | |
| SCHEMBL25814539 | 0.77 | HSPA5 (0.35) | PON1KMT2AMAPK1KDM4ERAB9A | |
| SCHEMBL10890673 | 0.77 | PON1 (0.35) | PON1KMT2AMAPK1KDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066378-A1 | SPIRO-OXAZOLONES | HOFFMANN-LA ROCHE INC. (US) | 2025-02-27 | — | — | US | disclosed |
| US-12162887-B2 | Spiro-oxazolones | HOFFMANN-LA ROCHE INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20230106150-A1 | SPIRO-OXAZOLONES | HOFFMANN-LA ROCHE INC. (US) | 2023-04-06 | — | — | US | disclosed |
| US-20200039997-A1 | SPIRO-OXAZOLONES | HOFFMANN-LA ROCHE INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-10479796-B2 | Spiro-oxazolones | HOFFMAN-LA ROCHE INC. (US) | 2019-11-19 | — | — | US | disclosed |
| EP-3083633-B1 | SPIRO-OXAZOLONES | HOFFMANN LA ROCHE (CH) | 2017-11-29 | — | — | EP | disclosed |
| US-20170008901-A1 | SPIRO-OXAZOLONES | HOFFMANN-LA ROCHE INC. (US) | 2017-01-12 | — | — | US | disclosed |
| EP-3083633-A1 | SPIRO-OXAZOLONES | F.HOFFMANN-LA ROCHE AG (CH) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015091411-A1 | SPIRO-OXAZOLONES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-25 | — | — | WO | disclosed |
| US-7189864-B2 | Method of preparing intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-0561948-B1 | PHOSPHONIC ACID DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS | UPJOHN CO (US) | 1995-04-05 | — | — | EP | disclosed |
| EP-0622373-A1 | Phosphonic acid derivatives useful as anti-inflammatory agents | THE UPJOHN COMPANY (US) | 1994-11-02 | — | — | EP | disclosed |
| US-5360797-A | Bisphosphonic acid derivatives useful as anti-arthritic agents | THE UPJOHN COMPANY (US) | 1994-11-01 | — | — | US | disclosed |
| EP-0414076-B1 | Cyclic substituted (quinoline-2-yl-methoxy)phenylacetic acid derivatives | BAYER AG (DE) | 1994-10-12 | — | — | EP | disclosed |
| US-5298498-A | Antiarthritic agents | THE UPJOHN COMPANY (US) | 1994-03-29 | — | — | US | disclosed |
| EP-0561948-A1 | PHOSPHONIC ACID DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS. | UPJOHN CO (US) | 1993-09-29 | — | — | EP | disclosed |
| US-5192771-A | Lipoxygenase inhibitors as antiinflammatory agents | BAYER AKTIENGESELLSCHAFT (DE) | 1993-03-09 | — | — | US | disclosed |
| WO-1992010504-A2 | PHOSPHONIC ACID DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS | THE UPJOHN COMPANY (US) | 1992-06-25 | — | — | WO | disclosed |
| EP-0414076-A1 | Cyclic substituted (quinoline-2-yl-methoxy)phenylacetic acid derivatives | BAYER AG (DE) | 1991-02-27 | — | — | EP | disclosed |
| US-3947471-A | CHROMOGENIC | SUMITOMO CHEMICAL COMPANY, LTD. (JA) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162887-B2 | Spiro-oxazolones | AVPR1A, AVPR1B, AVPR2 | PON1 2346/4885KMT2A 1376/4885MAPK1 3020/4885 |
| US-20250066378-A1 | SPIRO-OXAZOLONES | AVPR1A, AVPR1B, AVPR2 | PON1 2346/4885KMT2A 1376/4885MAPK1 3020/4885 |
| US-20200039997-A1 | SPIRO-OXAZOLONES | AVPR1A, AVPR1B, AVPR2 | PON1 2346/4885KMT2A 1376/4885MAPK1 3020/4885 |
| US-20170008901-A1 | SPIRO-OXAZOLONES | AVPR1A, AVPR1B, AVPR2 | PON1 2346/4885KMT2A 1376/4885MAPK1 3020/4885 |
| US-20230106150-A1 | SPIRO-OXAZOLONES | AVPR1A, AVPR1B, AVPR2 | PON1 2346/4885KMT2A 1376/4885MAPK1 3020/4885 |
| US-10479796-B2 | Spiro-oxazolones | AVPR1A, AVPR1B, AVPR2 | PON1 2346/4885KMT2A 1376/4885MAPK1 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.